SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001725160-22-000093
Filing Date
2022-05-05
Accepted
2022-05-05 07:09:59
Documents
69
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q zntl-20220331.htm   iXBRL 10-Q 1454775
2 EX-31.1 zentalis10-qq12022ex311.htm EX-31.1 10996
3 EX-31.2 zentalis10-qq12022ex312.htm EX-31.2 11228
4 EX-32.1 zentalis10-qq12022ex321.htm EX-32.1 5281
5 EX-32.2 zentalis10-qq12022ex322.htm EX-32.2 5676
  Complete submission text file 0001725160-22-000093.txt   5635190

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20220331.xsd EX-101.SCH 34117
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT zntl-20220331_cal.xml EX-101.CAL 67158
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20220331_def.xml EX-101.DEF 147371
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20220331_lab.xml EX-101.LAB 442611
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20220331_pre.xml EX-101.PRE 296337
63 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20220331_htm.xml XML 787064
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39263 | Film No.: 22894012
SIC: 2834 Pharmaceutical Preparations